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Endometrial Receptivity in 




Polycystic ovary syndrome (PCOS) is a frequent disorder affecting women of 
reproductive age characterized by infertility. Affected endometrial receptivity 
seems to contribute to decreased fertility of these patients as suggested by several 
studies. Understanding the mechanism behind this reduced endometrial receptivity 
could contribute to discovery of new therapeutic targets for infertility of PCOS. The 
aim of the paper is to review the current data regarding endometrial receptivity in 
PCOS patients, the potential mechanisms involved with particular focus on recent 
findings as the impact of gut microbiota on endometrium, the relationship between 
vitamin D and endometrial receptivity and the different impact of letrozole and 
clomiphene citrate on endometrial receptivity in infertile PCOS women.
Keywords: polycystic ovary syndrome, endometrial receptivity, endometrium, 
implantation, pregnancy
1. Introduction
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in 
women of reproductive age, having a prevalence of 8 to 13% and of 21% in high-risk 
groups [1]. Moreover, it is a leading cause of female infertility [2, 3] and the most 
common cause of anovulatory infertility [4]. A systematic review from 2020 [5] 
found that there is significant variation in prevalence probably according to ethnic 
background and design of the published studies, but also to diagnosis criteria used 
to identify the disease. Thus, they found that the reported prevalence of PCOS vary 
between 2,2% and 15–20%, with the studies using the Rotterdam criteria reporting 
the highest prevalence [5].
PCOS has significant consequences on the women health, being associated with 
infertility, menstrual irregularities, metabolic abnormalities, cardiovascular risk 
and psychological disturbances [6] and, therefore, impairing the quality of life. The 
latest guidelines [7] recommend the use of Rotterdam Consensus criteria for PCOS 
diagnosis, which assumes that two out of the following three features are present: 
oligo- or anovulation, hyperandrogenism (clinical or biochemical) and polycystic 
ovaries [8]. The use of these criteria generates several clinical phenotypes with 
variate impact on reproductive potential and metabolic profile, with some of them 
diagnosed with difficulty due to a scarce clinical picture. Therefore, PCOS can be a 
challenging disorder in the reproductive medicine practice.
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Hyperandrogenism is a key feature of PCOS, being the result of increased 
production of both ovarian and adrenal androgens. Ovarian over-secretion of 
androgens is the consequence of LH stimulation and also the action of high insulin 
levels on insulin receptors from the ovarian theca cells. Moreover, bioavailability 
of androgens is increased due to insulin effect to reduce the hepatic production of 
sex-hormone binding globulin.
2. Fertility in patients with polycystic ovary syndrome
PCOS is considered the most common cause of anovulation, being responsible 
for 70% of cases of anovulatory infertility [9]. Infertility is a significant complaint 
among women with PCOS, being reported in 72% of women with PCOS compared 
with 16% in women without PCOS. However, it seems that the number of children 
of women with PCOS is similar with those without, suggesting that treatment for 
infertility is effective [10].
It was also showed that 44% of women with unexplained infertility are prob-
able PCOS cases, underlying that the subtle clinical phenotypes in some of the 
patients can be the cause of misdiagnosis and, therefore, inappropriate diagnosis 
and treatment [11].
It seems that the criteria used for diagnosis can also impact the prevalence of 
infertility which is higher in women with polycystic ovary morphology in patients 
diagnosed according to Androgen Excess Society criteria (21,7%), while in patients 
diagnosed according to Rotterdam criteria infertility is present in only 6% of 
them [5].
Older studies report that 78% of infertile women with PCOS respond to clo-
miphene citrate (CC) administration [12], with only the remaining 22% requiring 
alternative therapies, suggesting that anovulation is not the only cause of infertility 
in PCOS patients. Indeed, even after restoration of ovulation, PCOS patients still 
have reduced cumulative pregnancy rate and higher rates of implantation failure 
[13]. Even in cycles with excellent embryos selected for transfer, the success of in 
vitro fertilization in PCOS patients remain low [14]. In animal models the transfer 
of blastocysts from normal mice to DHEA-induced PCOS mice resulted in a reduced 
implantation rate [15]. Moreover, patients with PCOS had an increased risk of 
miscarriage with reported rates between 30 and 50% of all conceptions [16, 17]. In 
addition, PCOS seems to be responsible for more than 30% of cases of recurrent 
miscarriages [18].
Since oocytes and embryo quality do not seems to be the cause of low implan-
tation and pregnancy rate in PCOS patients as demonstrated by donor oocyte 
models [19, 20], the decreased receptivity of the endometrium seems more 
probable. Indeed, accumulating data support the hypothesis that endometrium 
of PCOS patients is affected probably as a consequence of hormonal imbalance. 
Thus, unopposed estrogens, hyperinsulinemia, hyperandrogenism and the mem-
bers of insulin-like growth factor family were reported as possible contributors to 
endometrial pathology in PCOS [21]. Factors associated with unexplained recur-
rent pregnancy loss like high serum levels of free testosterone and LH, decreased 
luteal phase progesterone and delayed endometrial development [22] are also 
found in PCOS patients, suggesting their involvement in the high miscarriage rate 
in PCOS.
Several abnormalities of the endometrium were reported in PCOS women. 
Thus, endometrial gene expression and sex hormone receptors, co-receptors, 
adhesion molecules expression and endometrial markers were reported to be 
abnormal [23].
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3. Endometrial receptivity in women with polycystic ovary syndrome
Endometrial receptivity is a complex feature of the endometrium that allow the 
embryo to attach and invade the endometrium, and its further development into 
a viable fetus. For normal implantation both embryo and endometrial quality are 
important. In normal women the endometrium is receptive to embryo implantation 
for a period of 3–6 days which starts seven to ten days after ovulation known as the 
window of implantation. In pathological conditions this window can be shorten or 
shifted, resulting in infertility or pregnancy loss.
Human endometrium is a tissue whose development depends on the level of 
circulating hormones. During the follicular phase of the cycle, the increasing 
circulating estradiol levels determine the proliferation of the endometrial cells 
and increased endometrial sensitivity to estrogen through increasing the estrogen 
receptors (ER) ER-α levels [24, 25]. The ER expression is highest in the late prolif-
erative phase, decreasing in the luteal phase [25]. Following ovulation, the proges-
terone production determines inhibition of cellular proliferation, mitotic activity, 
DNA synthesis and stimulates the differentiation of the endometrial cells [26]. The 
inhibition of proliferation of the epithelial endometrial cells is the consequence of 
the progesterone-induced regulation of genes resulting in down regulation of estro-
gen receptors and the induction of the enzymes that metabolize estrogens reducing 
its cellular effects [26]. Moreover, progesterone reduces the expression of androgen 
receptor in endometrial cells and stroma [26]. As a consequence of all these changes 
the ‘window of implantation’ occur. Progesterone is also essential for decidualiza-
tion, a process that allow trophoblast invasion in case the implantation occur and 
establish a cytokine milieu and immunomodulatory network in the stroma. The 
decidualization is the consequence of endometrial stromal cells modifications of 
the cytoskeleton and up-regulation of prolactin, insulin-like growth factors, IGF 
binding proteins, insulin receptor and other factors. In the case the implantation 
does not occur, the decreasing estrogen and progesterone levels determines a shift 
from the expression of the innate immune genes to inflammatory genes expression 
in association with cellular apoptosis, increased production of metalloproteinases 
and prostaglandins, followed by endometrial desquamation and menstruation [26].
In women with PCOS, in the absence of ovulation the progesterone effects on 
the endometrium are lacking or severely decreased, affecting the decidualization 
and the window of implantation. Moreover, women with PCOS may have increased 
exposure to estrogen levels [27] as a consequence of aromatization of increased 
androgens in adipose tissue and decreased sex hormone binding globulin due to 
hyperinsulinemia [28, 29]. Several experimental studies support the alteration of 
endometrium especially in the window of implantation. Thus, Avellaira et al. [30] 
found that the tissue homeostasis in secretory endometrium of untreated women 
with PCOS is affected by an imbalance between apoptosis and cell proliferation 
which is increased as demonstrated by a study evaluating the expression of the 
proteins related with the two processes [30].
It was also suggested that some endometrial alterations in PCOS are the conse-
quence of prenatal intrauterine exposure to androgens being considered primary 
endometrial abnormalities [23]. Thus, the endometrium of PCOS women has a 
preponderance of estrogen and androgen action and decreased progesterone action 
as a consequence of hormone receptors expression and function.
3.1 Estrogen receptors (ER) expression and function
In PCOS patients the level of ER seems to be increased in all the cycle phases 
[31–35]. Moreover, some coactivators of the ER-α like TIF2 and AIB1 were also 
Infertility and Assisted Reproduction
4
found in higher levels in the proliferative endometrium of the PCOS patients 
compared with controls [32–35]. Moreover, during the proliferative phase, the 
endometrium of PCOS women showed a higher Bcl-2/Bax ratio, indicating the pre-
dominance of anti-apoptotic factors in the estrogen receptor increased environment 
[31]. The higher levels of mRNA and protein for ER-α and coactivators compared 
with normal women were reported in the mid-secretory phase endometrium of 
PCOS as well [32]. Moreover, the coactivator ARA70 was increase and epithelial 
expression of beta3-integrin, a protein involved in cell adhesion and cell surphace 
mediated signaling, was decreased in endometrium of PCOS versus control [32].
Enhanced ER-α activation was associated with rare or absent apoptosis and 
increased in cell proliferation in the endometrium in the mid luteal phase [30, 
36–38]. On the other hand, it is possible that high circulating estrogens as in 
patients performing ovarian stimulation to determine the apoptosis of the endome-
trial glandular cells, as showed by an experimental study by Chen et al. [39].
Other factors can contribute to increased exposure of endometrial cells to estro-
gens. Thus, the modified activity of the endometrial enzymes 17-β-hydroxysteroid 
dehydrogenase, which is downregulated and hydroxysteroid dehydrogenase type 
1, which is upregulated, could contribute to increased local production of estradiol 
and androstenediol with increased estrogenic activity [40–42].
3.2 Progesterone receptor (PR) expression and function
In endometrium of PCOS women progesterone receptors (PR) alpha and 
beta mRNA is overexpressed and the stromal immunostaining of PR-b and Ki67 
is higher compared with BMI-matched controls [43]. Moreover, an imbalance 
between PR-a expression and PR-b was found in proliferative endometrium of 
obese PCOS women, with the predominance of the later [43]. It was also reported 
that endometrial tissue of PCOS patients has decreased responsiveness to proges-
terone [44], also known as ‘P resistance’ [45]. This progesterone resistance might 
be due to reduced binding and activation of PR [46] or to an altered expression of 
its isoforms [46, 47]. Elevated PR isoform expression was showed to be associated 
with increased systemic levels of estrogen [48] and of androgen [49, 50]. Thus, 
hyperandrogenism modulates the expression and function of PR being associated 
with inactive or less active isoforms of PR [49–51], being probably responsible for 
progesterone resistance in PCOS women.
Mucin 1 (MUC1) is a progesterone-regulated molecule that carries selectin 
ligands recognized by the human blastocyst. Thus, Margarit et al. [52] showed that 
MUC1 expression is lower in anovulatory PCOS than in fertile patients, being a 
possible contributor to decreased implantation.
3.3 Androgen receptor
In the endometrium of PCOS women the androgen receptor (AR) mRNA and 
protein expression is increased [23] and coactivators of AR were found to be over-
expressed as well [37]. Among these coactivators, Melanoma-associated antigen 11 
(MAGEA11) was showed to bind to AR resulting in alteration of window of implan-
tation [11]. Endometrial microenvironment can also contribute to over-exposure 
to androgen. Thus, low level of SHBG can increase the bioavailable testosteron at 
endometrial level [53] and increased activity of endometrial 5a-reductase gener-
ates potent androgens such as di-hydro-testosterone [37]. The uptake of intracrine 
precursors of testosterone [38, 54] and increased activity of hydroxi-steroid-
dehydrogenase might contribute to high androgen exposure of endometrium in 
PCOS [55].
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3.4 Hyperandrogenism
During the mid-secretory phase of the menstrual cycle and the window of 
implantation the level of circulating androgens reach a nadir in normal cycles [56], 
while in PCOS patients with hyperandrogenism the level of circulating androgens 
is constantly increased. There is a significant body of evidence suggesting that 
overexposure to androgens may affect the normal development of endometrium 
and, therefore the endometrial receptivity. Thus, Cermik et al. [57] studied the 
effect of testosterone on HOXA10 expression in endometrium, a gene well known 
to be involved in endometrial receptivity. They demonstrated that, in vitro testos-
terone exposure decreases the expression on HOXA10 and prevents the increase of 
this gene in response to estrogen and progesterone [57]. They also confirmed that 
the expression of HOXA10 is decreased in the endometrium of the hyperandrogenic 
PCOS patients [57]. Homebox (HOX) are genes essential for endometrial receptiv-
ity which are maximally expressed in endometrium during the window of implan-
tation [58]. Their importance in implantation is demonstrated by experimental 
studies on female mice with disruption of HOXA10 which show infertility with 
implantation failure in spite of the presence of ovulation [59].
It was also showed that Wilms tumor suppressor (WT1) gene which is expressed 
in endometrium in the window of implantation, was downregulated in ovulatory 
women with PCOS in comparison with normal controls and that this downregula-
tion is the consequence of androgen exposure in in vitro models [60] Since high 
androgen are associated with elevated PR isoforms, it was suggested that hyperan-
dogenism could be a contributor to progesterone resistance found in PCOS women 
[50, 61]. High androgens can also affect the number and function of endometrial 
pinopodes which are associated with endometrial receptivity [62, 63]. Androgens 
can also influence the decidualization by their ability to modulate the oxidative 
stress response in decidualized endometrial cells [64] since the oxidative stress was 
showed to influence factors involved in embryo implantation like cytokeratin 8 
(CK-8) [65]. Other androgens can also act on endometrium. Thus, DHEA seems to 
block glucose utilization resulting in inhibition of decidualization [66] and modula-
tion of cell survival and apoptosis [67]. In pregnant mice treated with DHEA an 
impaired LIF-signal transducer and activator of transcription 3 (STAT3) pathway 
was observed, which was associated with implantation failure [68].
Clinical data showed that pregnant women with PCOS have lower endovascular 
trophoblast invasion in relation to circulating testosterone and the clinical pheno-
types involving hyperandrogenism [69, 70].
3.5 Hyperinsulinemia and insulin resistance
In clinical studies, in PCOS patients undergoing in vitro maturation-in vitro 
fertilization embryo transfer cycle insulin resistance was associated with decreased 
implantation, clinical pregnancy and ongoing pregnancy rates [71]. Energy metabo-
lism is vital for proper endometrial function taking into consideration the rapid 
turnover of endometrial tissue. Therefore, insulin action on endometrial tissue 
might be essential for endometrial receptivity. Insulin resistance and compensatory 
hyperinsulinemia can have detrimental effects on the implantation process as hyper-
insulinemia has been shown to impair stromal cell decidualization in vitro [72–74]. 
In PCOS endometrium several abnormalities in insulin signaling and glucose 
transport have been reported. Thus, hyperinsulinemia can reduce insulin receptor 
substrate 1 (InRS-1) activation and glucose transport in endometrial stromal cells in 
PCOS women [75–76], probably via inflammatory pathways [76, 77]. Experimental 
studies showed that in vitro exposure to dihydrotestosterone altered the expression 
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of insulin receptor and insulin receptor substrates and the phosphorylation of 
insulin receptor in endometrial stromal cells [74]. Other studies suggests that insulin 
action is decreased in endometrium of hyperinsulinemic women with PCOS, by 
showing that pAS160T642 and SLC2A4 which are substrates of insulin receptor are 
decreased in comparison with non-hyperinsulinemic PCOS and controls [75].
In vitro studies showed that insulin inhibits the production of IGFBP-1 in the 
endometrial stoma. IGFBP-1 is considered a biomarker of decidualization [73]. It 
is also possible that adiponectin, an insulin regulating molecule and regulator of 
glucose metabolism, which is decreased in PCOS patients, to be involved in endo-
metrial receptivity of these patients. Thus, adiponectin receptors were found to be 
highly expressed in the human endometrium during the window of implantation 
[78]. Moreover, decidualized mouse endometrium is able to secrete adiponectin and 
adiponectin receptors were found both in decidual cells and embryo after implanta-
tion [79]. This data supports the hypothesis that adiponectin might play a role in 
endometrial receptivity and implantation. Studies showing that metformin reduces 
the miscarriage rates in PCOS patients indirectly support the hypothesis of insulin 
resistance involvement in endometrial receptivity [80].
3.6 Vitamin D
Vitamin D deficiency is a frequent condition among women with infertility or 
PCOS. Numerous studies suggested a role of vitamin D in reproductive health at 
variate level of reproductive system, including endometrium. However, clinical 
data regarding the association between serum vitamin D level and endometrial 
pathology are divergent. A prospective controlled study [81] analyzed factors asso-
ciated with recurrent implantation failure and found higher prevalence of chronic 
endometritis, a lower vitamin D level and a borderline lower progesterone level in 
comparison with controls [81]. However, two recent systematic reviews found no 
association between serum vitamin D level and miscarriage rate in women who 
performed in vitro fertilization [82, 83], while one of these reviews reported higher 
pregnancy rates in vitamin D replete patients undergoing assisted reproduction 
treatments [82].
Experimental studies support the role of vitamin D in endometrial receptivity. 
Thus, Guo et al. [84] found that circulating level of vitamin D was positively associ-
ated with vitamin D receptor and HOXA10 protein level expression in the endo-
metrium and these were substantially elevated in pregnant women compared to 
non-pregnant women. During the window of implantation, higher serum vitamin 
D levels were associated with more mature pinopodes (84). Another study showed 
that in patients with recurrent implantation failure vitamin D treatment increases 
progesterone receptor mRNA and protein level and its phosphorylation on Ser294 
residues in the endometrial cells (85). These results suggest that vitamin D may play 
a key role in the endometrial receptivity [85].
In patients with PCOS vitamin D deficiency is frequently found [86]. However, 
specific data regarding the relationship between serum vitamin D and endo-
metrium in PCOS patients are scarce. Several studies reported that vitamin D 
treatment can improve the features associated with endometrial receptivity like 
hyperandrogenism [87], hyperinsulinism and insulin resistance [88], inflammation 
and oxidative stress [89].
In an experimental study in a rat model of PCOS it was found that immunohisto-
chemical staining of caspase-3 and Ki-67 were decreased with vitamin D treatment 
compared non-treated group [90]. Moreover, endometrial, epithelial and stromal 
thickness measurements were decreased in the vitamin D treatment group com-
pared to non-treated PCOS group [90].
7
Endometrial Receptivity in Patients with Polycystic Ovary Syndrome
DOI: http://dx.doi.org/10.5772/intechopen.98624
4. Strategies to improve endometrial function in PCOS
4.1 Ovulation induction agents
First-line treatment for ovulation induction in the treatment of infertility in 
PCOS are oral agents, with letrozole being superior to clomiphene citrate (CC) 
in terms of endometrial thickness and markers of endometrial receptivity  
[7, 91, 92]. Gonadotropins are the second line treatment and it seems that they 
have a less deleterious impact on endometrium [93]. However, no data today 
support the ovulation induction in infertile ovulatory PCOS for the modification 
of endometrial receptivity.
Several studies evaluated the different impact of ovarian stimulation with letro-
zole versus clomiphene citrate in patients with PCOS. Thus, Wallace et al. published 
in 2011 a randomized controlled study which reported that letrozole positively 
influenced a number of markers of endometrial receptivity like mRNA expression 
of leukemia inhibitory factor, dickkhopf homolog 1, fibroblast growth factor 22 
compared with CC [94]. Another randomized controlled study which included 160 
patients diagnosed with PCOS found that indices of endometrial receptivity like 
the volume, vascularization index, flow index and vascularization flow index of 
endometrium on the day of hCG administration and 7–9 days after ovulation were 
significantly increased in letrozole group compared with CC [95]. Moreover, the 
biochemical pregnancy rate, clinical pregnancy rate and ongoing pregnancy rate in 
letrozole group were significantly higher compared with CC group [95]. The same 
authors evaluated the indices of endometrial receptivity in treated PCOS patients 
(Letrozole or clomiphene citrate) and non-treated [96]. They noticed that, although 
the successful ovulation rate did not differ between the letrozole group and CC 
group, endometrial thickness, endometrial volume, vascularization index, flow 
index, vascularization flow index, integrin αvβ3 and VEGF concentrations in uterine 
fluid were significantly higher in the window of implantation in the letrozole group 
compared with the CC group and natural cycle group [96]. Moreover, the clinical 
pregnancy and ongoing pregnancy rates of the letrozole group were significantly 
higher than in the CC group [96]. The markers of endometrial receptivity analyzed 
were significantly higher in pregnant patients [96]. The endometrial flow index 
during the implantation window had the highest predictive value for pregnancy. The 
integrin αvβ3 in uterine fluid had better predictive value than VEGF [96].
In an experimental study on female rats it was found that the expression of inte-
grin αvβ3 in the clomiphene citrate group was lower than in the letrozole and saline 
solution groups [97]. The expression of HOXA10 was statistically significantly 
higher in the saline solution group than in the letrozole group, and the letrozole 
group showed a statistically significantly higher expression of HOXA10 compared 
with the clomiphene citrate group. The authors concluded that, in rats, letrozole 
affects the expression of HOXA10 in uterine epithelium but has no effect on the 
expression of integrin αvβ3, which suggests that clomiphene suppresses endome-
trial receptivity more than letrozole.
4.2 Antiandrogens
Antiandrogens as flutamide, finasteride and spironolactone are used in clinical 
practice to improve the signs of clinical hyperandrogenism like hirsutism, acne, 
alopecia. Animal studies demonstrated the ability of antiandrogens to improve 
endometrial function [98, 99]. However, their use in patients seeking infertility 
treatment is prohibited by their teratogenic effects, being generally recommended 
to be administrated only in association with oral contraception [100]. Another way 
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to improve hyperandrogenism is by administration of combined oral contraceptives 
which decrease ovarian androgen production and decrease androgen bioavail-
ability through stimulation of sex hormone binding globulin production. Indeed, 
oral contraceptives, administrated in a successive or unsuccessive manner before 
in vitro fertilization, were showed to increase the implantation and pregnancy rate 
and reduce the risk of pregnancy complications along with significant decrease in 
circulating androgens [101]. However, in a randomized controlled trial ovulation 
rate and live birth rate were superior in PCOS patients receiving life style modifi-
cation with or without oral contraceptive in comparison with oral contraceptive 
alone [102].
4.3 Freeze all strategy
Elective frozen embryo transfer after a freeze-all strategy was suggested for 
infertile PCOS patients undergoing IVF [103]. This approach could be particularly 
effective in PCOS due to exposure of the endometrium to high estrogen levels 
during controlled ovarian stimulation. Thus, transfer of the embryo in a subsequent 
cycle may avoid failure of implantation due to inadequate endometrium receptivity. 
This strategy was showed of particular benefit in PCOS patients and only in case 
of more than 16 oocytes or estradiol higher than 3000 pg./ml, resulting in higher 
live birth rate [104]. Regarding the preparation of endometrium, it seems that the 
pregnancy rate is higher in natural cycles over the hormone replacement cycles in 
women performing frozen embryo transfer [105]. However, specific data for PCOS 
women are lacking.
In women with PCOS, no difference in live birth/ongoing pregnancy and clinical 
pregnancy rates was detected between FET cycles stimulated with hMG and cycles 
artificially prepared with E2 valerate [106–108].
4.4 Gut microbiota and endometrial receptivity
There is accumulating evidence that gut microbiota might play a role in PCOS 
pathogenesis [109, 110]. Thus, it was showed that gut microbiota of PCOS patients 
is different from controls [111] and that variate profiles of gut microbiota are associ-
ated with features of PCOS such as hyperandrogenism [112], hyperinsulinemia and 
insulin resistance [113] and obesity [114]. In experimental studies transplantation 
of feces from PCOS women leads to development of PCOS features in mice [109] 
and oral administration of variate bacteria was associated with improvement of 
PCOS manifestation [110]. Thus, Qi X et al. [109] showed that Bacteroides vul-
gatus was markedly elevated in the gut microbiota of individuals with PCOS and 
that transplantation of fecal microbiota from women with PCOS or B. vulgatus-
colonized recipient mice resulted in increased disruption of ovarian functions, 
insulin resistance, altered bile acid metabolism, reduced interleukin-22 secretion 
and infertility [109]. It was also showed that IL-22 improved the PCOS phenotype 
[109]. Guo Y et al. [110] showed that PCOS rats displayed different composition of 
gut microbiota that in the controls. Lactobacillus, Ruminococcus and Clostridium 
were lower while Prevotella was higher in PCOS rats when compared with control 
rats. After treating PCOS rats with Lactobacillus and fecal microbiota transplanta-
tion from healthy rats estrous cycles were improved with decreasing androgen 
biosynthesis [110].
However, it is possible that the relationship between gut microbiota and PCOS 
to be bidirectional since in androgen-induced PCOS animal models the distur-
bances of gut microbiota was reported [115, 116]. In turn, DHEA-shaped gut 
microbiota transplanted to pseudo germ-free rats recipients trigged disturbances in 
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reproductive hormone [115]. Another study showed that both androgens and high 
fat diet could shift the overall gut microbial composition, being associated with the 
development and pathology of PCOS by shaping gut microbial communities [117]. 
Although direct evidence of a connection between gut microbiota and endometrial 
receptivity was not reported yet, we can hypothesize a connection between these 
two due to the recognized involvement of insulin resistance, hyperandrogenemia 
and obesity in endometrial receptivity which, in turn, can be shaped by intestinal 
bacterial community.
Regarding the mechanisms connecting gut microbiota and PCOS, Tremellen 
and Pearce suggest that dysbiosis of the gut microbiota brought about by a high 
fat-sugar diet in PCOS patients leads to an increase in intestinal permeability. 
Lipopolysaccharide produced by Gram-negative bacteria traverse the gut wall 
to enter the circulation, leading to a chronic state of low-grade inflammation. 
Activation of the immune system interferes with insulin receptor, driving up insulin 
levels, which boost testosterone production in the ovary, leading to PCOS [118].
Another way by which gut microbiota might influence the endometrial receptiv-
ity is through its recently demonstrated close connection with genital tract micro-
biota [119–122]. The crosstalk between gut and vaginal microbiota is highlighted 
by studies showing that oral administration of probiotics or bacteria can influence 
immunity in the vagina [120]. Thus, oral administration of Lactobacillus johnsonii 
was showed to inhibit the expression of inflammatory molecules in the vagina and 
to alleviate Gardnerella vaginalis induced vaginosis [122]. Kutteh et al. [121] dem-
onstrated that intestinal tract immunization by oral and rectal route is followed by 
the induction of specific antibodies in human female genital tract secretions [Kutteh 
2001]. Kim et al. [120] showed that in ovarectomized female mice, the oral admin-
istration of anti-inflammatory Lactobacillus plantarum NK3 and Bifidobacterium 
longum NK49 from kimchi and human fecal lactic acid bacteria collection was 
associated with alleviation of Gardnerella vaginalis induced vaginosis, inhibition of 
NF-κB activation and TNF-α expression in the vagina and uterus, and decreased the 
Gardnerella vaginalis population in the vagina [120]. In turn, Gardnerella vaginalis-
induced vaginosis increased colonic myeloperoxidase activity, TNF-α expression, 
and fecal Proteobacteria population. NK3 and/or NK49 treatments reduced TNF-α 
expression and NF-κB activation in the colon and restored Gardnerella vaginalis 
disrupted gut microbiota composition [120].
This interplay between gut and reproductive tract microbiota may be related 
with endometrium function since, recently, it was showed that pathological modi-
fication of the profile of the bacterial community of the endometrial fluid might 
play a role in poor reproductive outcome for in vitro fertilization patients [123]. 
Thus, the presence of a non-Lactobacillus-dominated microbiota in a receptive 
endometrium was associated with significant decreases in implantation, pregnancy, 
ongoing pregnancy, and live birth rates [123]. Haahr et al. [124] found a decreased 
pregnancy rate in patients with abnormal vaginal microbiota performing IVF [124]. 
These studies highlight the importance of reproductive tract microbiota in fertility, 
possibly by modulation of endometrial receptivity.
All these data offer future therapeutic strategies to counteract decreased 
endometrial receptivity in PCOS women by modulating gut or reproductive tract 
microbiota or by administration of interleukin 22 as suggested by Qi X et al. [109].
4.5 Assessment of endometrial receptivity and therapeutical implications
The evaluation of endometrial receptivity was historically done by endometrial 
histology. However, recent studies find little concordance with new transcriptomic 
methods of endometrial receptivity assessment [125]. Endometrial receptivity array 
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(ERA) is a test that analyzes the gene expression of the endometrium using a panel 
of 238 genes that have been implicated in endometrial receptivity. The indication of 
this test in the clinical practice is to identify the window of implantation in patients 
with accelerated or delayed endometrial luteal phase development, therefore allow-
ing the transfer of the embryo in the right moment for the embryonic-endometrial 
synchrony. However, data regarding the benefit of this test are limited [126]. 
Although in PCOS patients performing IVF ERA test has hypothetical indications, 
studies evaluating this aspect are lacking.
Another aspect that should be clarified further is the consistency of the ERA 
findings from cycle to cycle since the transfer of the embryo should be done in a 
non-biopsy cycle. This aspect was analyzed in seven women who performed the 
ERA test in separate endometrial samples obtained 29–40 months apart and found 
high similarity across the samples [127]. However, only five samples were from the 
luteal phase and only four were in the receptive phase, all the samples being normal. 
Therefore, the possibility to extrapolate these findings to patients with endome-
trium receptivity abnormalities or dyssynchrony is unknown.
The ERA test was studied in several categories of infertile patients. Tan et al. 
[128] found that among patients with a history of at least one euploid blastocyst 
implantation failure personalized frozen embryo transfer (FET) according to ERA 
test results was superior to standard FET in terms of implantation and ongoing preg-
nancy rate, although the difference was not statistically different [128]. Other studies 
showed a similar pregnancy rate between patients with receptive and non-receptive 
endometrium according to the ERA test when a personalized embryo transfer was 
performed in patients with recurrent implantation failure [129] or with a history of 
implantation failure [125]. On the other hand, Eisman et al. [130] found a similar 
pregnancy rate in women who had a prior failed embryo transfer and personalized 
frozen embryo transfer following ERA test compared with women without a prior 
failed embryo transfer [130]. However, the pregnancy rate was lower in patients with 
more than three failed embryo transfer despite personalized transfer [130].
A multicenter, open-label randomized controlled trial evaluated patients at their 
first appointment for IVF after exclusion of patients with recurrent miscarriage and 
implantation failure. They found that a personalized frozen embryo transfer guided by 
ERA test was superior in terms of cumulative pregnancy and live birth rate to standard 
frozen embryo transfers and fresh embryo transfers [131]. At the first embryo transfer 
cycle, although the pregnancy rate and implantation rates were significantly higher 
compared with the two groups without ERA guidance, the live birth rates were similar 
[131]. Basil et al. [132] performed a single center retrospective cohort study and found 
that using the ERA test in patients undergoing frozen embryo transfer, there is no 
benefit in terms of ongoing pregnancy rate in good prognosis patients [132].
Taken all together, these studies suggest that the ERA test might be beneficial in 
patients with implantation failure, although future studies are necessary to clarify 
this aspect. In patients at their first attempt of IVF personalized frozen embryo 
transfer guided by ERA test may increase the cumulative pregnancy and live birth 
rate, although without obvious benefits at the first transfer. Whether these results 
are also valid for PCOS patients remains to be established.
5. Conclusion
An increasing body of evidence suggests that endometrial receptivity in PCOS 
patients is decreased, being a significant contributor to infertility in these patients. 
However, specific strategies to overcome this barrier in infertile PCOS women 
should be created in order to improve fertility treatment outcome.
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